NEW YORK, April 9 - Eisai, a Japanese health care and pharmaceutical company, has signed a multi-year subscription to Incyte Genomics' LifeSeq Gold human sequence and ZooSeq animal model databases, the company said Monday.

Researchers at Eisai, which is based in Tokyo, will have 24-hour online access to the databases and to information technology support, Incyte said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.